May 2019: Changes to Reference Ranges & Test Builds

Special Communication

Reference Range Changes

Cysticercus IgG Ab, Serum (CYSGBL)

Effective immediately.

Reference Range

< or = 0.8 IV: Negative
No significant level of cysticercosis IgG antibody detected

0.9 – 1.1 IV: Equivocal
Questionable presence of cysticercosis IgG antibody detected; repeat testing in 10-14 days may be helpful

> or = 1.2 IV: Positive
IgG antibodies to cysticercosis detected, which may suggest current or past infection

Liver Fibrosis, FibroTest-ActiTest (LIVFIB)

Effective June 3, 2019.

Reference Range

Apolipoprotein A1
– Male: > or = 115 mg/dL
– Female: > or = 125 mg/dL

Note: There will be no other range changes

Galactose Quant, Plasma (GALAC)

Effective June 4, 2019.

Reference Range

< or = 7 days: < 5.4 mg/dL

8 – 14 days: < 3.6 mg/dL

> or = 15 days: < 2.0 mg/dL

Hemoglobin A2 (HBA2)

Effective July 2, 2019.

Reference Range

2.0 – 3.1%

Hemoglobin A2 and F (A2F)

Effective July 2, 2019.

Reference Range

Hemoglobin Fetal: 0.0 – 0.9%

Hemoglobin A2 Percent: 2.0 – 3.1%

Hemoglobin Fetal (HBF)

Effective July 2, 2019.

Reference Range

0.0 – 0.9%

Vancomycin (VANCRA)

Effective July 9, 2019.

Reference Range

0 – 99 Years: 10.0 – 20.0 µg/mL

Test Build Changes

These updates may require changes to the Test Build for interfaced clients.

Effective May 30, 2019.

Spinal Muscular Atrophy Carrier Screening and Diagnostic (SMAGEN)

Effective June 11, 2019.

Paraneoplastic Autoantibody Evaluation, CSF (PARCSF)

Discontinued Tests

Degradation Products (FDP)

Effective immediately.

Due to the lack of availability of the appropriate tubes, this test has been discontinued.

We suggest ordering D-Dimer (DDMER).

Any additional information regarding these changes will be included in a future Technical Update.

If you have any questions about this change, please contact Client Services for assistance.

CCL Featured Stories, Homepage Featured Stories, Resources, Special Communication